A Phase 3 Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting With Acute Coronary Syndrome Treated With Losmapimod Compared to Placebo (LATITUDE-TIMI 60)

NCT02145468 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

3503

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Coronary Syndrome

Interventions

DRUG: Losmapimod 7.5 mg twice daily
DRUG: Placebo twice daily
DRUG: Standard therapy

Sponsor

GlaxoSmithKline

Collaborators

[object Object]